TimesSquare Capital Management LLC Has $11.63 Million Stock Holdings in GH Research PLC (NASDAQ:GHRS)

TimesSquare Capital Management LLC lessened its stake in GH Research PLC (NASDAQ:GHRSGet Rating) by 0.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 498,299 shares of the company’s stock after selling 2,300 shares during the quarter. TimesSquare Capital Management LLC owned 0.99% of GH Research worth $11,625,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in GHRS. VR Adviser LLC increased its stake in GH Research by 28.7% in the 3rd quarter. VR Adviser LLC now owns 1,642,296 shares of the company’s stock valued at $36,229,000 after buying an additional 366,465 shares during the period. Morgan Stanley increased its stake in GH Research by 110.3% in the 3rd quarter. Morgan Stanley now owns 424,260 shares of the company’s stock valued at $9,359,000 after buying an additional 222,532 shares during the period. RA Capital Management L.P. increased its stake in GH Research by 1.2% in the 3rd quarter. RA Capital Management L.P. now owns 3,013,957 shares of the company’s stock valued at $66,488,000 after buying an additional 35,002 shares during the period. Citadel Advisors LLC increased its stake in GH Research by 2.2% in the 3rd quarter. Citadel Advisors LLC now owns 1,312,646 shares of the company’s stock valued at $28,300,000 after buying an additional 28,856 shares during the period. Finally, Geode Capital Management LLC acquired a new position in shares of GH Research during the 3rd quarter worth $599,000. Hedge funds and other institutional investors own 56.72% of the company’s stock.

Several brokerages have recently commented on GHRS. Canaccord Genuity Group dropped their price target on shares of GH Research from $45.00 to $41.00 and set a “buy” rating on the stock in a research note on Wednesday, April 13th. Zacks Investment Research raised shares of GH Research from a “sell” rating to a “hold” rating in a report on Tuesday, February 8th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, GH Research has a consensus rating of “Buy” and an average target price of $33.05.

Shares of GHRS stock traded down $0.52 during trading hours on Monday, hitting $18.90. The company had a trading volume of 337 shares, compared to its average volume of 87,353. GH Research PLC has a 12 month low of $12.38 and a 12 month high of $30.43. The stock’s fifty day moving average is $17.68.

GH Research Company Profile (Get Rating)

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

Recommended Stories

Want to see what other hedge funds are holding GHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GH Research PLC (NASDAQ:GHRSGet Rating).

Institutional Ownership by Quarter for GH Research (NASDAQ:GHRS)

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.